Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Envoy Medical, Inc. (COCH)

6.51 +0.01 (+0.15%)
At close: October 27 at 4:00:01 PM EDT
6.50 -0.01 (-0.15%)
Pre-Market: 8:48:59 AM EDT
Chart Range Bar
Loading chart for COCH
  • Previous Close 6.50
  • Open 6.41
  • Bid 0.69 x 400
  • Ask 6.90 x 100
  • Day's Range 5.97 - 7.05
  • 52 Week Range 3.63 - 9.54
  • Volume 40,382
  • Avg. Volume 10,791
  • Market Cap (intraday) 50.384M
  • Beta (5Y Monthly) 1.95
  • PE Ratio (TTM) --
  • EPS (TTM) -7.60
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 21.67
  • Zacks Rating Neutral

Envoy Medical, Inc., a hearing health company, provides medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

www.envoymedical.com

43

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 10/27/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

COCH
1.51%
S&P 500 (^GSPC)
12.81%

1-Year Return

COCH
19.63%
S&P 500 (^GSPC)
12.33%

3-Year Return

COCH
53.50%
S&P 500 (^GSPC)
87.56%

5-Year Return

COCH
93.31%
S&P 500 (^GSPC)
69.66%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 51k
Earnings -7.27M
Profit Margin -14,258.82%

Q2

FY25

Q3

FY25

Q1

FY26

Q2

FY26

-6M
-4M
-2M
0
-18000.0%
-16000.0%
-14000.0%
-12000.0%
-10000.0%

Analyst Insights

View More

Analyst Price Targets

20.00
21.67 Average
6.51 Current
25.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/6/2026
Analyst Lake Street
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 2.5

Statistics

View More

Valuation Measures

Annual
As of 10/26/2026
  • Market Cap

    50.31M

  • Enterprise Value

    31.44M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    175.45

  • Price/Book (mrq)

    15.19

  • Enterprise Value/Revenue

    151.87

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -86.53%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    207k

  • Net Income Avi to Common (ttm)

    -28.46M

  • Diluted EPS (ttm)

    -7.60

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    19.68M

  • Total Debt/Equity (mrq)

    21.93%

  • Levered Free Cash Flow (ttm)

    -8.22M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

6.51 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: